Values First Advisors Inc. Takes $128,000 Position in Inari Medical, Inc. (NASDAQ:NARI)

Values First Advisors Inc. bought a new position in Inari Medical, Inc. (NASDAQ:NARI) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 3,116 shares of the company’s stock, valued at approximately $128,000.

Several other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Inari Medical by 6.9% during the 4th quarter. Vanguard Group Inc. now owns 5,038,292 shares of the company’s stock valued at $327,086,000 after buying an additional 325,586 shares in the last quarter. State of Alaska Department of Revenue lifted its holdings in Inari Medical by 462.4% in the 1st quarter. State of Alaska Department of Revenue now owns 31,095 shares of the company’s stock worth $1,491,000 after purchasing an additional 25,566 shares in the last quarter. Maryland State Retirement & Pension System bought a new position in Inari Medical in the 1st quarter worth approximately $886,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Inari Medical during the 1st quarter valued at approximately $30,000. Finally, Texas Permanent School Fund Corp raised its position in shares of Inari Medical by 1.5% during the first quarter. Texas Permanent School Fund Corp now owns 44,858 shares of the company’s stock valued at $2,152,000 after buying an additional 664 shares during the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on NARI shares. Piper Sandler reaffirmed a “neutral” rating and set a $50.00 target price on shares of Inari Medical in a research note on Monday, August 26th. Stifel Nicolaus initiated coverage on Inari Medical in a report on Tuesday, September 17th. They issued a “hold” rating and a $50.00 target price on the stock. Wells Fargo & Company dropped their price target on Inari Medical from $84.00 to $65.00 and set an “overweight” rating for the company in a research note on Wednesday, July 31st. Canaccord Genuity Group lifted their price objective on Inari Medical from $55.00 to $71.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Finally, Robert W. Baird lowered their target price on Inari Medical from $65.00 to $63.00 and set an “outperform” rating for the company in a research report on Wednesday, July 31st. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $57.44.

Insiders Place Their Bets

In other news, CFO Mitch C. Hill sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $45.13, for a total transaction of $135,390.00. Following the transaction, the chief financial officer now owns 179,600 shares of the company’s stock, valued at approximately $8,105,348. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CFO Mitch C. Hill sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $47.99, for a total value of $239,950.00. Following the transaction, the chief financial officer now owns 179,600 shares of the company’s stock, valued at $8,619,004. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Mitch C. Hill sold 3,000 shares of Inari Medical stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $45.13, for a total transaction of $135,390.00. Following the sale, the chief financial officer now owns 179,600 shares of the company’s stock, valued at $8,105,348. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 88,000 shares of company stock valued at $4,009,340 over the last 90 days. Insiders own 10.60% of the company’s stock.

Inari Medical Stock Performance

NASDAQ:NARI opened at $43.70 on Friday. The stock’s fifty day moving average is $43.65 and its 200 day moving average is $45.86. The firm has a market capitalization of $2.54 billion, a PE ratio of -106.59 and a beta of 1.00. Inari Medical, Inc. has a fifty-two week low of $36.73 and a fifty-two week high of $67.13.

Inari Medical (NASDAQ:NARI) last announced its earnings results on Tuesday, July 30th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.25). Inari Medical had a negative net margin of 10.42% and a negative return on equity of 7.51%. The firm had revenue of $145.82 million during the quarter, compared to analysts’ expectations of $143.96 million. Equities analysts forecast that Inari Medical, Inc. will post -0.75 EPS for the current year.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.